Shanghai Model Organisms Center, Inc. (SHA:688265)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Custom Model	33.91M			38.11M	42.48M	-	-
Custom Model Growth	-			-10.28%	-	-	-
Standardized Model	164.77M			94.91M	53.44M	-	-
Standardized Model Growth	-			77.59%	-	-	-
Model Breeding	90.06M			74.85M	56.82M	-	-
Model Breeding Growth	-			31.72%	-	-	-
Drug Efficacy Evaluation and Phenotypic Analysis	53.20M			38.15M	18.08M	-	-
Drug Efficacy Evaluation and Phenotypic Analysis Growth	-			111.06%	-	-	-
Feeding Service	29.97M			24.98M	22.40M	-	-
Feeding Service Growth	-			11.51%	-	-	-
Other Model Biotechnology Services	6.58M			2.63M	2.34M	-	-
Other Model Biotechnology Services Growth	-			12.56%	-	-	-
Biotechnology	-			-	-	154.80M	121.44M
Biotechnology Growth	-			-	-	27.47%	-
Total	378.49M			273.64M	195.56M	154.80M	121.44M
Total Growth	-			39.92%	26.33%	27.47%	59.83%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
China	325.43M			-	-	154.80M	121.44M
China Growth	-			-	-	27.47%	63.97%
Overseas	53.06M			-	-	-	-
Total	378.49M			-	-	154.80M	121.44M
Total Growth	-			-	-	27.47%	59.83%

Source: S&P Global Market Intelligence.